dsdsa

product

Bottom price Doxorubicin - USP EP BP Medicine Grade 148408-66-6 Docetaxel trihydrate for Treatment of Tumor Cancer – Yibai

Short Description:


Product Detail

FAQ

Product Tags

Related Video

Feedback (2)

With responsible good quality method, good status and excellent client services, the series of solutions produced by our company are exported to lots of countries and regions for Anti-Viral Drugs, 171596-29-5, Hepatitis C Virus Inhibitor, Welcome worldwide customers to contact us for business and long-term cooperation. We will be your reliable partner and supplier of auto parts and accessories in China.
Bottom price Doxorubicin - USP EP BP Medicine Grade 148408-66-6 Docetaxel trihydrate for Treatment of Tumor Cancer – Yibai Detail:

Product name Docetaxel Trihydrate
Synonyms (αR,βS)-β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-benzenepropanoic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,hydrate (1:3)
CAS No. 148408-66-6
Appearance White to off-white crystalline powder
Molecular Formula C43H53NO14.3(H2O)
Molecular Weight 861.94
Application Pharma grade or research purpose
Packing As per your request
Storage Preserve in tight,light-resistant containers in a cool place

 

Docetaxel Trihydrate CAS# 148408-66-6

ITEMS

STANDARDS

RESULTS

Characters A:White to off-white crystalline powder Conforms
B:Solubility :Insoluble in water ,soluble in ethanol and acetone   Conforms
Specific Rotation             ﹣38.5°~﹣41.5° ﹣40°
Identification 1.IR:  The same to check sample    Conforms
2.UV:  λmax232nm    Conforms
  1. Colour reactions: positive reactions
   Conforms
  1. HPLC: retention times is same as the standard sample
   Conforms
Impurities Total impurities: NMT 1.0% 0.29%
Impurities A: NMT 0.5% 0.0551%
Impurities B: NMT 0.3% 0.0470%
Impurities C: NMT 0.3% 0.0535%
Any other single impurity: NMT 0.1% 0.0702%
Water 5.0% – 7.0% 6.15%
Residue on ignition NMT 0.1% w/w 0.03%
Heavy metal NMT 20ppm Conforms
Assay 97.5%~ 102.0% 99.7%
Conclusion

It meets EP7.5.

Company Information

√ Management layer’s full experience in factory and skilled technicians followers;
√ Quality is always our top consideration, Strict QC system;
√ 11 years experienced exporting sales team;
√ Independent R&D lab;
√ Two signed long term GMP workshops;
√ Rich resources of plenty idle factories for customized project;
√ High Efficiency working team with consistent path.
imgsafSDGSHDASFG

Product detail pictures:

Bottom price Doxorubicin - USP EP BP Medicine Grade 148408-66-6 Docetaxel trihydrate for Treatment of Tumor Cancer – Yibai detail pictures

Bottom price Doxorubicin - USP EP BP Medicine Grade 148408-66-6 Docetaxel trihydrate for Treatment of Tumor Cancer – Yibai detail pictures

Bottom price Doxorubicin - USP EP BP Medicine Grade 148408-66-6 Docetaxel trihydrate for Treatment of Tumor Cancer – Yibai detail pictures


Related Product Guide:

Our rewards are lower costs,dynamic profits team,specialised QC,potent factories,high-quality services for Bottom price Doxorubicin - USP EP BP Medicine Grade 148408-66-6 Docetaxel trihydrate for Treatment of Tumor Cancer – Yibai , The product will supply to all over the world, such as: Hanover, Pakistan, Iran, we are now looking forward to even greater cooperation with overseas customers based on mutual benefits. We will work wholeheartedly to improve our products and services. We also promise to work jointly with business partners to elevate our cooperation to a higher level and share success together. Warmly welcome you to visit our factory sincerely.
  • The manufacturer gave us a big discount under the premise of ensuring the quality of products, thank you very much, we will select this company again.
    5 Stars By Aurora from Czech - 2018.11.28 16:25
    Product quality is good, quality assurance system is complete, every link can inquire and solve the problem timely!
    5 Stars By Emily from United Kingdom - 2018.02.08 16:45
    Write your message here and send it to us